Regular purchasing channels for rubicatin/rubitigine

Lurbinectedin, as an emerging anti-cancer drug for advanced small cell lung cancer (SCLC), has been launched by the US pharmaceutical company PharmaMar and has been approved for marketing in many countries and regions. An original injection dosage form has been approved for marketing in China, with a specification of 4mg/bottle, but it has not yet been included in the national medical insurance directory, which means that patients still need to bear higher out-of-pocket costs if they need medication. In the domestic market, the price of each box of original medicine is usually more than 20,000 yuan, and may fluctuate slightly depending on exchange rate fluctuations.

As a transit market, Hong Kong and Macao also provide original research versions. The channels are relatively formal, but the prices are also maintained at a high level. In the international market, the US version and Singapore version of the original drug of rupitidine are currently widely circulated, but the price is more expensive, and a box may cost thousands of dollars. It is worth noting that there are currently no generic drugs of rubitidine on the market, which means that the drugs on the market are all original research versions. Whether it is a domestically marketed version or an overseas imported version, its drug ingredients and efficacy remain the same.

In terms of legal purchases, patients can choose to purchase from formal medical institutions or drug import platforms approved by the State Food and Drug Administration to avoid drug quality and safety risks caused by purchasing drugs through informal channels. Some patients also choose to purchase drugs after remote consultation through hospitals or legally qualified overseas drug purchase institutions. However, they must pay attention to providing real case information, prescription information, and receiving evaluation from professional doctors to ensure that they meet the treatment indications and receive standardized medication guidance.

Overall, although the current price of rupitidine is relatively high, its clinical value in recurrent small cell lung cancer has been internationally recognized and it is available through domestic and foreign channels. In the future, as policy changes or generic drugs are launched, the price is expected to gradually decrease.

Reference materials:https://www.zepzelca.com/